IBDEI13Z ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17988,1,3,0)
 ;;=3^Multi-System Degeneration of the Autonomic Nervous System
 ;;^UTILITY(U,$J,358.3,17988,1,4,0)
 ;;=4^G90.3
 ;;^UTILITY(U,$J,358.3,17988,2)
 ;;=^5004162
 ;;^UTILITY(U,$J,358.3,17989,0)
 ;;=G91.2^^61^795^22
 ;;^UTILITY(U,$J,358.3,17989,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17989,1,3,0)
 ;;=3^NPH w/ Dementia w/ Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,17989,1,4,0)
 ;;=4^G91.2
 ;;^UTILITY(U,$J,358.3,17989,2)
 ;;=^5004174^F02.81
 ;;^UTILITY(U,$J,358.3,17990,0)
 ;;=G91.2^^61^795^23
 ;;^UTILITY(U,$J,358.3,17990,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17990,1,3,0)
 ;;=3^NPH w/ Dementia w/o Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,17990,1,4,0)
 ;;=4^G91.2
 ;;^UTILITY(U,$J,358.3,17990,2)
 ;;=^5004174^F02.80
 ;;^UTILITY(U,$J,358.3,17991,0)
 ;;=G30.8^^61^795^5
 ;;^UTILITY(U,$J,358.3,17991,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17991,1,3,0)
 ;;=3^Alzheimer's Diseases NEC
 ;;^UTILITY(U,$J,358.3,17991,1,4,0)
 ;;=4^G30.8
 ;;^UTILITY(U,$J,358.3,17991,2)
 ;;=^5003807
 ;;^UTILITY(U,$J,358.3,17992,0)
 ;;=G31.09^^61^795^16
 ;;^UTILITY(U,$J,358.3,17992,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17992,1,3,0)
 ;;=3^Frontotemporal Dementia NEC
 ;;^UTILITY(U,$J,358.3,17992,1,4,0)
 ;;=4^G31.09
 ;;^UTILITY(U,$J,358.3,17992,2)
 ;;=^329916
 ;;^UTILITY(U,$J,358.3,17993,0)
 ;;=G20.^^61^795^24
 ;;^UTILITY(U,$J,358.3,17993,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17993,1,3,0)
 ;;=3^Parkinson's Disease w/ Dementia w/ Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,17993,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,17993,2)
 ;;=^5003770^F02.81
 ;;^UTILITY(U,$J,358.3,17994,0)
 ;;=G20.^^61^795^25
 ;;^UTILITY(U,$J,358.3,17994,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17994,1,3,0)
 ;;=3^Parkinson's Disease w/ Dementia w/o Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,17994,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,17994,2)
 ;;=^5003770^F02.80
 ;;^UTILITY(U,$J,358.3,17995,0)
 ;;=G31.01^^61^795^26
 ;;^UTILITY(U,$J,358.3,17995,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17995,1,3,0)
 ;;=3^Pick's Disease
 ;;^UTILITY(U,$J,358.3,17995,1,4,0)
 ;;=4^G31.01
 ;;^UTILITY(U,$J,358.3,17995,2)
 ;;=^329915
 ;;^UTILITY(U,$J,358.3,17996,0)
 ;;=G23.1^^61^795^28
 ;;^UTILITY(U,$J,358.3,17996,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17996,1,3,0)
 ;;=3^Progressive Supranuclear Ophthalmoplegia
 ;;^UTILITY(U,$J,358.3,17996,1,4,0)
 ;;=4^G23.1
 ;;^UTILITY(U,$J,358.3,17996,2)
 ;;=^5003780
 ;;^UTILITY(U,$J,358.3,17997,0)
 ;;=Z79.2^^61^796^1
 ;;^UTILITY(U,$J,358.3,17997,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17997,1,3,0)
 ;;=3^Antibiotics
 ;;^UTILITY(U,$J,358.3,17997,1,4,0)
 ;;=4^Z79.2
 ;;^UTILITY(U,$J,358.3,17997,2)
 ;;=^321546
 ;;^UTILITY(U,$J,358.3,17998,0)
 ;;=Z79.01^^61^796^2
 ;;^UTILITY(U,$J,358.3,17998,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17998,1,3,0)
 ;;=3^Anticoagulants
 ;;^UTILITY(U,$J,358.3,17998,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,17998,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,17999,0)
 ;;=Z79.02^^61^796^3
 ;;^UTILITY(U,$J,358.3,17999,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17999,1,3,0)
 ;;=3^Antiplatelets/Antithrombotics
 ;;^UTILITY(U,$J,358.3,17999,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,17999,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,18000,0)
 ;;=Z79.82^^61^796^4
 ;;^UTILITY(U,$J,358.3,18000,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18000,1,3,0)
 ;;=3^Aspirin
